Compare FTHY & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTHY | EOLS |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 539.8M | 444.0M |
| IPO Year | N/A | 2018 |
| Metric | FTHY | EOLS |
|---|---|---|
| Price | $14.05 | $5.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.50 |
| AVG Volume (30 Days) | 176.7K | ★ 891.1K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 10.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $285,823,000.00 |
| Revenue This Year | N/A | $14.24 |
| Revenue Next Year | N/A | $21.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 15.10 |
| 52 Week Low | $12.66 | $5.71 |
| 52 Week High | $14.74 | $17.12 |
| Indicator | FTHY | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 50.29 | 29.49 |
| Support Level | $13.98 | $6.57 |
| Resistance Level | $14.15 | $6.80 |
| Average True Range (ATR) | 0.09 | 0.27 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 53.63 | 6.23 |
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income. The fund invests a majority of its managed assets in high-yield debt securities of any maturity that are rated below investment grade at the time of purchase or unrated securities. Its investment portfolio comprises corporate bonds and notes, senior floating-rate loan interests, foreign corporate bonds and notes, money market funds, and other instruments across various industries.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.